Press & news - FluoGuide A/S

23 August, 2022 FluoGuide has submitted a Clinical Trial Application (CTA) to the Danish Medicines Agency to initiate phase II trial with FG001 in head and neck cancer News Corporate Information Other Corporate Information English IR

Following approval from the Danish Medicines Agency, FluoGuide will initiate the phase II trial in collaboration with Department of...

22 August, 2022 Publication of clinical data confirming uPAR as an attractive target for guiding surgery in head and neck cancer News Corporate Information Other Corporate Information English IR

The article documents the relevance of uPAR as target for guiding surgery of head and neck cancers relative to other molecular targets...

31 May, 2022 FluoGuide A/S publishes interim report for the period January – March 2022 News English Regulatory Listing Regulation Report Interim Q1 IR

. *) Result per share (DKK per share): Operating result divided by the average number of shares during the period. The total number...

6 May, 2022 FluoGuide invites to presentation of FG001 results from the first clinical trial in aggressive brain cancer on 17 May 2022 News Corporate Information Other Corporate Information English IR

As a follow-up on the presentation done by Principal Investigator and Chief Surgeon Jane Skjøth-Rasmussen in Bergen, FluoGuide...

2 May, 2022 Annual General Meeting Copenhagen, Denmark, 2 May 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) hereby convenes an annual general meeting to be held on 18 May 2022. News Corporate Information General meeting Notice English Regulatory Listing Regulation IR

The board of directors hereby convenes an annual general meeting of FluoGuide to be held on: Wednesday 18 May 2022 at 11:00 (CET) at...

1 April, 2022 FluoGuide announces positive top line result from the first part of the ongoing clinical phase I/II trial testing the safety and performance of FG001 in lightening up aggressive brain cancer News Corporate Information Other Corporate Information English Regulatory MAR IR

In total, 40 patients have been administered and FG001 has been shown safe and well tolerated (please see table). No serious drug related...

30 March, 2022 FluoGuide A/S publishes Year-end and annual report for the fiscal year 2021 News English Regulatory Listing Regulation Report Annual IR

KEY FINANCIAL FIGUES Q4 2021 Full Year 2021 (Audited) HIGHLIGHTS FROM 2021 Q1 Q2 Q3 Q4 HIGHLIGHTS AFTER THE PERIOD For further information...

29 March, 2022 FluoGuide A/S issue warrants to employees and management News Corporate Information Other Corporate Information English IR

Today, the Board of Directors of FluoGuide has exercised its authorization to issue new warrants by issuing 40,000 warrants to employees...

24 March, 2022 FluoGuide has received approval from the Danish Medicines Agency to initiate phase II trial with FG001 in lung cancer News Corporate Information Other Corporate Information English IR

Following approval from the Danish Medicines Agency and Ethical Committee, FluoGuide will initiate enrolment a phase II trial in lung...

2022

FluoGuideCalendar & events